Shock is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Shock have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Shock compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Shock overview
Shock is a medical condition characterized by a significant and life-threatening drop in blood flow throughout the body. This reduction in blood flow deprives the organs and tissues of the necessary oxygen and nutrients, leading to cellular dysfunction and potential organ failure. Shock is a critical condition that requires prompt and appropriate medical intervention. Symptoms include rapid heart rate, confusion, low blood pressure, and cold, clammy skin. Immediate medical intervention is vital to restore blood flow, stabilize blood pressure, and address the underlying cause, as untreated shock can lead to organ failure or death.
For a complete picture of PTSR and LoA scores for drugs in Shock, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.